- Home
- BWAY vs EVMN Comparison
BWAY vs EVMN Comparison
Compare BWAY & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BWAY | EVMN |
|---|---|---|
| Founded | 2003 | 2020 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.7M | 474.7M |
| IPO Year | 2011 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BWAY | EVMN |
|---|---|---|
| Price | $13.42 | $8.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $13.25 | ★ $43.88 |
| AVG Volume (30 Days) | 75.3K | ★ 677.7K |
| Earning Date | 05-13-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | $309.69 | N/A |
| Revenue Next Year | $26.21 | N/A |
| P/E Ratio | $81.98 | ★ N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $11.77 | $8.11 |
| 52 Week High | $26.63 | $33.20 |
Technical Indicators
Market Signals| Indicator | BWAY | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 36.69 | 26.03 |
| Support Level | $11.90 | N/A |
| Resistance Level | $14.83 | $13.35 |
| Average True Range (ATR) | 0.54 | 0.52 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 22.30 | 9.59 |
Price Performance
Historical ComparisonAbout BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.